ADRB2 rs1042714: What Your Genotype Means
The rs1042714 variant is a common genetic variation located in the ADRB2 gene, which provides instructions for making the beta-2-adrenergic receptor. This single nucleotide polymorphism has been moderately associated with how individuals, particularly those with asthma, respond to beta-agonist bronchodilator medications. While research indicates it may influence airway hypersensitivity and asthma control, the clinical evidence remains mixed and should be interpreted alongside a doctor's guidance.
What each genotype means
| Genotype | What the research suggests | Reading |
|---|---|---|
| CC | Individuals with the CC genotype have two copies of the major C allele. In pharmacogenomic research, this genotype is generally considered the baseline or standard type for beta-2-adrenergic receptor function, though individual response to asthma medications will still vary based on other factors. | Informational |
| CG | Individuals with the CG genotype carry one C allele and one G allele. Studies show mixed evidence regarding this genotype's impact on asthma severity and bronchodilator response, meaning it does not definitively predict how well beta-agonist medications will work for you. | Informational |
| GG | Individuals with the GG genotype have two copies of the minor G allele, which alters the receptor's amino acid sequence (Gln27Glu). Some studies suggest this genotype may be associated with differences in asthma control or airway responsiveness over time, warranting standard clinical monitoring if asthma symptoms persist. | Higher attention |
What is rs1042714 and the ADRB2 Gene?
The rs1042714 single nucleotide polymorphism (SNP) is located within the ADRB2 gene on human chromosome 5. This gene is responsible for encoding the beta-2-adrenergic receptor, a crucial protein belonging to the G protein-coupled receptor superfamily. In the human body, these receptors are activated by catecholamines like adrenaline and epinephrine, playing a vital role in relaxing smooth muscle tissues, particularly in the airways of the lungs. Because of this function, the beta-2-adrenergic receptor is the primary target for beta-agonist medications, such as albuterol, which are widely used to treat asthma and other respiratory conditions by inducing bronchodilation. The rs1042714 variant, often referred to in scientific literature as Gln27Glu or Q27E, involves a substitution of the nucleotide cytosine (C) with guanine (G). This change alters the amino acid sequence of the receptor protein, replacing glutamine with glutamic acid at position 27. Researchers study this structural change to understand if it affects how well the receptor functions or how it interacts with asthma medications.
Research and Pharmacogenomic Associations
Research into rs1042714 primarily focuses on its pharmacogenomic implications, specifically how it might influence a patient's response to beta-agonist inhalers used in asthma treatment. Some studies and meta-analyses suggest that variations at this locus can affect airway hypersensitivity, asthma severity, and bronchodilator response. For instance, certain longitudinal studies have observed that the G allele may be associated with age-related changes in bronchodilator response or a higher risk of difficult-to-control asthma when combined with other ADRB2 variants. However, the overall evidence strength is considered moderate and sometimes mixed. Several large-scale analyses have found no significant relationship between rs1042714 genotypes and acute bronchodilator response, especially in patients chronically using long-acting beta-agonists. Because the scientific consensus is not absolute, this variant is viewed as one piece of a complex genetic puzzle rather than a definitive predictor of medication efficacy. The mixed findings highlight that asthma drug response is likely influenced by a combination of multiple genetic factors, environmental triggers, and the specific type of medication used.
Population Frequency of rs1042714
The rs1042714 variant is common across global populations, though the exact frequency of its alleles varies significantly by ancestry. The cytosine (C) allele is generally the most common major allele, while the guanine (G) allele is the minor allele. According to historical data from the Centers for Disease Control and Prevention and various genomic databases, the C allele appears in roughly 64 percent of the general population, with the G allele making up the remaining 36 percent. Consequently, the heterozygous CG genotype is highly prevalent, seen in about 43 percent of individuals, closely followed by the homozygous CC genotype at 42 percent. The homozygous GG genotype is the least common, appearing in approximately 15 percent of people. Studies have noted distinct intercontinental variability; for example, the G allele frequency can be notably lower in certain Native American or specific Asian cohorts compared to Caucasian populations. These differences underscore the importance of considering genetic ancestry when evaluating population-wide pharmacogenomic trends.
What You Can and Cannot Do With This Information
Understanding your rs1042714 genotype can provide educational insight into how your genetics might interact with certain respiratory medications, but it has strict limitations for personal healthcare. You cannot use this genetic information to diagnose asthma, predict disease severity, or determine your exact response to an inhaler. Most importantly, you should never alter, reduce, or stop taking prescribed asthma medications, such as short-acting or long-acting beta-agonists, based on a genetic test result. The evidence linking this specific variant to drug response is moderate and mixed, meaning it is not currently used in standard clinical practice to guide prescription dosing. If you have asthma and are curious about how your genetic profile might affect your treatment, you should discuss these findings with a qualified healthcare provider or a clinical pharmacist. They can evaluate your medication regimen using a comprehensive approach that includes your medical history, lung function tests, and overall symptom control.
How common is this variant?
The rs1042714 variant is common globally, with the C allele appearing in roughly 64 percent of the general population and the G allele in about 36 percent. Genotype frequencies typically distribute as approximately 42 percent for CC, 43 percent for CG, and 15 percent for GG, though these proportions can vary significantly across different ancestral groups.
Frequently asked questions
What is the ADRB2 gene?
The ADRB2 gene provides instructions for making the beta-2-adrenergic receptor, a protein found on smooth muscle cells in the lungs and other tissues. This receptor responds to adrenaline and is the primary target for beta-agonist medications used to open airways in asthma patients.
Does the rs1042714 variant cause asthma?
No, rs1042714 does not directly cause asthma. While some studies have investigated its association with asthma susceptibility and severity, it is primarily studied for its potential role in how the body responds to asthma medications.
Should I change my asthma medication based on my rs1042714 genotype?
Absolutely not. You should never change, start, or stop any medication based solely on a genetic test result. Always discuss your asthma treatment and any pharmacogenomic concerns with your doctor or pharmacist.
Why is the evidence for this variant considered moderate or mixed?
Scientific studies on rs1042714 have yielded conflicting results; some show a link between the variant and altered responses to beta-agonists, while others show no significant effect. This inconsistency means the variant is just one of many genetic and environmental factors influencing asthma treatment.
What does the Gln27Glu (Q27E) notation mean?
Gln27Glu, or Q27E, is the scientific notation describing the protein change caused by the rs1042714 variant. It means that at position 27 of the beta-2-adrenergic receptor protein, the amino acid glutamine (Gln/Q) is replaced by glutamic acid (Glu/E) due to the genetic substitution of a G allele for a C allele.
Sources & further reading
Educational information only, last refreshed 9/4/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs1042714?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in ADRB2
This polymorphism is associated with altered beta-2 adrenergic receptor function and potential differences in asthma medication response.
A missense variant in the Beta-2 Adrenergic Receptor gene that may influence response to asthma inhalers and exercise-induced lipolysis.
This variant is associated with altered response to beta-agonist medications used in asthma treatment.
This SNP is involved in the regulation of beta-2 adrenergic receptor function and response to asthma medication.
This polymorphism is linked to variations in bronchodilator response in patients with respiratory conditions.
ADRB2 Gly16Arg alters beta-2 receptor function; influences heart-rate and blood-pressure response to exercise.